gmp review

analysing international pharmaceutical regulations

Hand Disinfection Regulations – a mud bath?

Rethinking Valve Technology in Pharma: Why It's Time to Move from Weir to Radial Diaphragm Valves

Evolving Landscape of Pyrogen Testing

What does Precision Medicine mean for the Pharmaceutical Supply Chain and GMDP?

GMP SOCIETY

Vol.23 No.1 January 2026

Rethinking Valve Technology in Pharma: Why It's Time to Move from Weir to Radial Diaphragm Valves

by John Swibes and David Grote

In the pharmaceutical industry, where patient safety is paramount, many facilities still rely on legacy systems and traditional weir-style sanitary diaphragm valves. These technologies, developed decades ago, were not designed to meet today's rigorous standards for cleaning validation, contamination control, and long-term maintainability. As regulations tighten and the industry shifts toward smarter, leaner, more efficient, and more hygienic production platforms, it's critical for process engineers, project managers, and regulatory leaders to ask a key question: Are our current valves holding us back from achieving true aseptic performance?

The Regulatory Landscape and the Reluctance to Change

Adopting new technologies in a regulated environment is inherently challenging. While regulatory frameworks are meticulously designed to ensure product safety and consistency, they can inadvertently slow down innovation. The four main hurdles that historically make change difficult are:

1. **Change Assessment and Planning:** Regulatory bodies demand detailed justification and comprehensive documentation for any process modification. The initial burden of evaluating a proposed change, designing a robust implementation roadmap, and justifying it through meticulous risk assessments is a time-consuming, resource-intensive process that can stall projects before they even begin.
2. **Production Stockpiling:** If a modification impacts validated production lines, facilities often need to stockpile final product to maintain supply during the transition. This creates significant logistical, financial, and storage burdens that can make decision-makers hesitant to proceed.
3. **Scheduling and Production Demands:** The pharmaceutical sector operates on lean, tightly scheduled production campaigns. Finding sufficient downtime to install and test new valves without disrupting critical timelines is a major operational challenge, often perceived as too costly or complex.
4. **Validation and Regulatory Approval:** This is frequently cited as the most formidable obstacle. The need to revalidate the updated process, prove equivalency or demonstrable superiority to existing methods, and secure the full confidence of regulatory inspectors is both resource-intensive and introduces perceived risk, regardless of the actual benefits.

A Historic Opportunity for Change: The New Construction Boom

Today, these traditional barriers are being re-evaluated in the face of an unprecedented wave of capital investment. Major players in the pharmaceutical industry are strategically moving away from outsourced manufacturing models and are actively building new, state-of-the-art facilities within the United States. This strategic shift aims to secure supply chains, enhance resilience, and meet evolving market demands for advanced therapeutics.

This surge in investment, with companies committing to over $400 Billion in US biopharma-ceutical development, presents a monumental, once-in-a-generation opportunity. These new facilities are being designed from the ground up to be future-proof, with a sharp focus on advanced manufacturing principles, automation, and intrinsically hygienic design. Crucially, the decision on which core components to specify – especially at the process core – is being made now, before the inertia and cost of retrofitting a legacy system take hold.

This moment is not just about replacing old parts; it's about embedding a superior process philosophy from the very start of a facility's lifecycle.

Why the case for change is stronger than ever

Whether you are retrofitting an existing line or specifying components for a new facility, the case for replacing traditional weir-style diaphragm valves with true aseptic radial diaphragm valves is compelling, offering profound technical, operational, and economic advantages – see **Figure 1**.



***Figure 1**. The P&ID (Piping and Instrumentation Diagram) on the left uses symbols representing traditional weir valves. In this design, a main valve is paired with a small branch valve, commonly referred to as a Sterile Access Port. These branch connections create "dead legs"—sections of piping where fluid can become trapped. The orientation of the branch makes this problem evident: a downward-facing leg can retain product and condensate during steam-in-place (SIP) sterilization, while an upward-facing leg can trap a pocket of cold air that is difficult to sterilize using standard SIP procedures.*

The P&ID on the right illustrates a different approach using radial diaphragm divert valves. By opening or closing the blocking valve (represented in the diagram by the ">" symbol), product is routed only through the piping needed to reach the intended destination. This design eliminates dead legs entirely. It also allows critical utilities—such as steam, purified water, and cleaning agents—to be introduced through an additional series of divert valves. As a result, the system uses the minimum necessary piping while maintaining full sterility without creating trapped or stagnant zones.

The business case is straightforward: eliminating dead legs reduces cleaning variability, lowers water and chemical consumption, and improves product recovery.

1. Engineered for Modern Aseptic Standards

Traditional weir valves (**Figure 2**), by their very design, create inherent dead zones and geometric inconsistencies that complicate full drainability and significantly increase the risk of microbial ingress and proliferation. Another disadvantage of these dead zones in sanitary piping is product loss. Valuable material can be trapped in these stagnant sections and cannot be effectively recovered, resulting in unnecessary waste.This makes them fundamentally incompatible with modern Cleaning-in-Place (CIP) and Sterilization-in-Place (SIP) protocols, often necessitating aggressive cycles or manual intervention.

***Figure 2**. The weir membrane valve showing considerable dead leg.*

In contrast, radial diaphragm valves (**Figures 3a and 3b**) are designed with clean, symmetrical, and compact valve chambers that effectively eliminate dead legs and stagnant pockets. This innovative design ensures complete drainability and robust cleanability, thereby significantly reducing the risk of contamination and dramatically simplifying validation efforts. Modular porting options allow for highly customized configurations without compromising the valve's fundamental hygienic integrity, leading to optimized layouts and reduced pipework.

2. Superior Sealing with Solid PTFE Diaphragms

Traditional molded thin-film diaphragms frequently suffer from porosity due to their manufacturing process and typically require an elastomer backing. This multi-layered construction introduces another potential point of failure, particularly during repeated SIP cycles where steam can permeate, condense, and cause blistering.

New innovative approaches employ a solid, precision-machined PTFE diaphragm. This specially modified PTFE exhibits zero porosity, and its structural integrity over time is vastly superior to that of layered or backed diaphragm

systems. The result is a diaphragm that seals more reliably, lasts considerably longer, and is exceptionally resistant to aggressive cleaning chemicals and the high temperatures characteristic of modern SIP processes — all critical attributes in aseptic and high-purity environments.

3. Lower Total Cost of Ownership (TCO)

While the initial procurement cost of a premium radial diaphragm valve may appear to be higher than conventional alternatives, the long-term savings delivered across the operational lifecycle are substantial. By significantly reducing cleaning and validation time, reducing chemical and energy use, minimizing contamination risk, and inherently improving process reliability, these advanced valves translate directly into tangible, real-world cost benefits. Facilities can anticipate reduced downtime, minimized product loss from costly batch failures, lower cleaning chemical and utility costs, and fewer component change-outs, all of which contribute to a dramatically lower Total Cost of Ownership.

4. Proven and Validated Performance

Skeptics often express hesitation, fearing the risks associated with being "first adopters" of new technology. However, this technology is anything but new or experimental. Radial diaphragm valves have been reliably in service since 1991, and the solid PTFE diaphragm has been extensively proven in critical aseptic applications since 2012. These components are already thoroughly validated and are in routine use at top-tier pharmaceutical companies globally. By making this transition, your facility is not taking a pioneering risk; rather, you are aligning with a proven movement already embraced by leading innovators in the field.

Conclusion: The Future is Aseptic, Efficient, and Radial

Change within the pharmaceutical industry is notoriously challenging, especially when it directly impacts the core of a validated process. Nevertheless, such change is often not just beneficial but absolutely necessary for progress and long-term sustainability. The current wave of multibillion-dollar investments in new, cutting-edge facilities is a clear and undeniable signal that the industry is ready to shed outdated practices and embrace new technologies that align with future demands.

It is a stark reality that if weir valves were invented today, their inherent geometry would simply not meet current aseptic design standards. They are fundamentally based on an outdated philosophy that necessitates excessive maintenance, introduces unacceptable risks, and presents formidable obstacles



Figures 3a and 3b. *Examples of radial divert valves with no dead legs.*



to both validation and process optimization.

Radial diaphragm valves represent far more than just a better valve. They embody a superior philosophy of process design: intrinsically hygienic by geometry, inherently efficient by design, and comprehensively validated by extensive experience in the most demanding pharmaceutical applications. Facilities that begin this transition today are not merely adopting a new component; they are strategically embracing a foundational platform for cleaner, leaner, more compliant, and ultimately more productive manufacturing operations tomorrow.

Now is the time to take this essential step forward. Not because it is easy. But because it is demonstrably the right thing to do for both patient safety and your operational bottom line.

***John Swibes** is an industry specialist with more than 30 years of technical sales experience as a business owner supporting the biopharmaceutical and hygienic process sectors. His work has focused on advancing fast-to-clean, high-reliability technologies that enhance sterility, operability, and compliance within GMP manufacturing environments.*

A recognized expert in magnetically coupled mixer systems—top-mounted, bottom-mounted, stainless-steel, and single-use, and has introduced several innovations in mixing, sampling, and cryogenic storage valves that are now widely adopted across the industry. John holds a patent for a single-use cell recovery device.

Over the past decade, he has concentrated on next-generation aseptic valve technologies, particularly zero-dead-leg designs that enable clean, compact, and efficient process systems. He works closely with engineering teams across North America and Europe to implement hygienic solutions that reduce contamination risk, support validation, and improve system performance.

***David Grote** is the VP of Strategy for GrayMatter Partners and a Principal Consultant for Curadian Group. Over 25 years, including leadership roles at Amgen, Teva, and Immunocore, David has leveraged his extensive operational experience to turn the industry's most complex quality challenges into commercial success. David brings his experience to clients, leveraging data-driven strategies and innovative solutions to de-risk global operations, accelerate approvals, and ensure successful, inspection-ready, and cost-effective processes. As a strategist, he actively partners with transformative technology and service providers; including those specializing in system and facility engineering, AI, quality systems, and analytical instrumentation; to drive transformative improvements across the often change-resistant biopharmaceutical industry.*

Call for papers and articles

Dear Colleague,

We hope you find **GMP Review** of interest and practical use in your specialty. We are currently seeking new papers and articles for future issues of the journal and would like to invite you to contribute an article or review paper to the journal. We would welcome papers on any aspects of regulations including pharmaceutical manufacturing and control.

We invite you and your colleagues to address any of the above suggestions and on any other topics that you think may be relevant and of interest to readers of **GMP Review**.

Thank you for your continued support

Yours sincerely
Tim Sandle